| Ulcerative Colitis
Zeposia vs Abrilada
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Zeposia vs Abrilada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAbrilada has a higher rate of injection site reactions vs Zeposia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Abrilada but not Zeposia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zeposia
Abrilada
At A Glance
Oral
Once daily
S1P receptor modulator
SC injection
Every 1-2 weeks
TNF-alpha blocker
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Ulcerative Colitis
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
Dosing
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis Weight-based SC dosing every other week for patients 2 years of age and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction then 20 mg every other week (<40 kg) or 40 mg every other week (>=40 kg) starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Week 8 (Day 57).
Psoriasis vulgaris, Uveitis 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Contraindications
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
- Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Severe untreated sleep apnea
- Concurrent use of a monoamine oxidase (MAO) inhibitor
—
Adverse Reactions
Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)
Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome
Postmarketing Liver injury
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, nausea, urinary tract infection, sinusitis, hyperlipidemia, flu syndrome, abdominal pain, back pain, hypercholesterolemia, hypertension
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, malignancies, hepatitis B reactivation, demyelinating disorders, hematologic reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, systemic vasculitis, deep vein thrombosis
Pharmacology
Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.
Adalimumab-afzb is a recombinant human IgG1 monoclonal antibody TNF-alpha blocker that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammation and modulating TNF-induced biological responses including leukocyte migration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zeposia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Abrilada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Zeposia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Abrilada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zeposia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Abrilada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zeposia.
No savings programs available for Abrilada.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZeposiaView full Zeposia profile
AbriladaView full Abrilada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.